Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CMPX 
Compass Therapeutics Inc. (CMPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CMPX (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.2
1 Year Target Price $13.2
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 192.79% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 598.79M USD | Price to earnings Ratio - | 1Y Target Price 13.2 |
Price to earnings Ratio - | 1Y Target Price 13.2 | ||
Volume (30-day avg) 9 | Beta 1.3 | 52 Weeks Range 1.27 - 4.08 | Updated Date 08/29/2025 |
52 Weeks Range 1.27 - 4.08 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.12 | Actual -0.14 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.14% | Return on Equity (TTM) -51.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 391560918 | Price to Sales(TTM) 439.25 |
Enterprise Value 391560918 | Price to Sales(TTM) 439.25 | ||
Enterprise Value to Revenue 109.28 | Enterprise Value to EBITDA -8.92 | Shares Outstanding 138282000 | Shares Floating 100795496 |
Shares Outstanding 138282000 | Shares Floating 100795496 | ||
Percent Insiders 11.42 | Percent Institutions 62.63 |
Upturn AI SWOT
Compass Therapeutics Inc.
Company Overview
History and Background
Compass Therapeutics, Inc. is a biopharmaceutical company focused on developing proprietary antibody-based therapeutics to treat multiple human diseases. Founded to create multi-specific antibodies, it has built a pipeline of antibody therapeutics.
Core Business Areas
- Oncology Therapeutics: Developing antibody-based therapeutics targeting the immune system to fight cancer.
Leadership and Structure
Details on leadership and organizational structure are difficult to confirm without up-to-date information, this is primarily a research firm
Top Products and Market Share
Key Offerings
- CTX-471: CTX-471 is a fully human IgG1 bispecific antibody that simultaneously targets the co-stimulatory receptor CD137 and the inhibitory receptor PD-1. Development ongoing. Market share is not applicable as the products are in clinical development. Potential competitors include larger pharma companies with established immuno-oncology pipelines (e.g., Roche, Merck, Bristol Myers Squibb).
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically immuno-oncology, is experiencing significant growth, driven by advancements in antibody engineering and a growing understanding of the immune system's role in cancer. This is a highly competitive market
Positioning
Compass Therapeutics is a smaller player in the biopharmaceutical space, focusing on novel antibody therapies. Its competitive advantage lies in its proprietary antibody platform and specific target combinations.
Total Addressable Market (TAM)
The TAM for immuno-oncology is estimated to be billions of dollars annually. Compass Therapeutics is positioned to capture a portion of this market with successful clinical development and commercialization of its pipeline products.
Upturn SWOT Analysis
Strengths
- Proprietary antibody platform
- Focus on novel immuno-oncology targets
- Experienced management team (unconfirmed)
- Potential for high-value partnerships
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with drug development
- Dependence on successful clinical trial outcomes
- No currently marketed products
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion of pipeline through internal research and development
- Potential for breakthrough therapies in underserved markets
- Advancements in antibody engineering technologies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
Competitive Landscape
Compass Therapeutics faces strong competition from established pharmaceutical companies with greater resources. It must differentiate itself through innovative therapies and strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development progress, partnership deals, and financing activities.
Future Projections: Future growth is dependent on clinical trial success, regulatory approvals, and commercialization of its therapies. Analyst estimates would provide specific revenue and earnings projections.
Recent Initiatives: Recent initiatives include advancing clinical trials, securing partnerships, and exploring new therapeutic targets.
Summary
Compass Therapeutics is a small biopharmaceutical company with a focus on innovative antibody therapies. Its future depends on successful clinical trials and strategic partnerships to compete with larger firms. Financial performance and clinical progress are key indicators of its viability. The company operates in a competitive landscape and faces inherent risks in drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The biopharmaceutical industry is inherently risky, and investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Therapeutics Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-04-05 | CEO & Vice Chairman Dr. Thomas J. Schuetz M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | |
Full time employees 35 | |||
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.